NBIX
Neurocrine Biosciences Inc (NBIX)
Healthcare • NASDAQ • $152.25+1.78%
- Symbol
- NBIX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Price
- $152.25
- Daily Change
- +1.78%
- Market Cap
- $15.31B
- Trailing P/E
- 23.42
- Forward P/E
- 11.60
- 52W High
- $160.18
- 52W Low
- $116.00
- Analyst Target
- $190.99
- Dividend Yield
- N/A
- Beta
- 0.34
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's dise…
Company websiteResearch NBIX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.